Introduction
The number of women worldwide affected by gestational diabetes mellitus (GDM) is on the rise (1) . Healthcare providers are struggling to find the most appropriate screening methods, diagnostic criteria, and guidelines for this ever-increasing population. Even when guidelines are nationally applied, very little is known about their effect on their most important goal: pregnancy outcomes.
Gestational diabetes mellitus is defined as glucose intolerance first encountered during pregnancy (2) . However, ª 2016 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 96 (2017) 372-381 some degree of insulin resistance, and hence a higher demand for insulin, is encountered even during a normal pregnancy (3) . There is an ongoing discussion regarding the optimal screening method and diagnostic criteria to identify the true GDM mothers in this group, and several clinical practices are currently in use worldwide (4) . Pregnancies complicated by GDM are associated with maternal and fetal risks in pregnancy and later in life, such as an increased risk of operative deliveries, preeclampsia, fetal macrosomia, asphyxia, and hypoglycemia (5) (6) (7) (8) (9) . The mother has a high risk of developing diabetes mellitus type II (10) , and the child may suffer from metabolic disturbances and obesity later in life (11) .
The prevalence of GDM is 5-16% depending on the population, screening, and diagnostic criteria used (4, 12, 13) . In Finland, GDM is diagnosed using a 2-h 75-g oral glucose tolerance test (OGTT). The same diagnostic criteria have been used for several years in Helsinki metropolitan area hospitals, allowing a remarkable increase to be demonstrated, as the prevalence of GDM was 8.5% in 2006, but reached 16.0% in 2014 (14) .
It has been reported that despite the increased prevalence of GDM due to changes in the diagnostic criteria and screening, the outcomes have remained unaffected (15) . Conversely, significantly improved pregnancy outcomes and cost savings have been found in a Spanish cohort study when the new International Association of the Diabetes and Pregnancy Study Groups criteria were applied. This study included universal screening (16) . However, when comparing the shift from risk-based to comprehensive screening in a Finnish study, the prevalence of GDM increased, but the population-based study was unable to find evidence regarding the optimal screening method (17) . The National Institute of Health and Care Excellence guidelines published in 2015 recommend risk-based screening if a woman has one or several of the following risk factors: body mass index (BMI) >30 kg/m 2 , a previous macrosomic baby, a family history of diabetes, or a minority ethnic family of origin with a high prevalence of diabetes. Hence the challenge is to find evidencebased guidelines and criteria for screening, diagnosis, and treatment practices for GDM.
The Finnish Medical Society Duodecim, together with various medical specialist societies, published the Current Care Guidelines (CCG) for GDM in 2008. The aim was to provide national, evidence-based clinical practice guidelines for screening, diagnostic criteria, and treatment of GDM (18) . Before the CCG release in 2008, a risk-based screening had been carried out for GDM if an expecting mother had glucosuria, BMI ≥25 kg/m 2 , age ≥40 years, fetal macrosomia in a current or previous pregnancy, GDM in a previous pregnancy, or diabetes mellitus among first-degree relatives. These risk-based criteria had been used in Helsinki metropolitan area hospitals before 2008, but usage elsewhere in Finland may have varied. The new CCG recommended GDM screening for nearly all mothers with singleton or multiple pregnancy between 24 and 28 weeks of gestation and emphasized that screening should be performed comprehensively, the only exception being those at very low risk (18) . The CCG defined low-risk nulliparous mothers as women aged <25 years who had BMI 18.5-25 kg/m 2 and whose first-or seconddegree family members did not have diabetes mellitus type 2. Low-risk parous women were defined as age <40 years and BMI <25 kg/m 2 without a previous macrosomic (>4500 g) baby. As a result of these new guidelines, the number of OGTTs performed between 2006 and 2011 on expectant mothers in Finland doubled (19). By studying the various maternal and neonatal outcomes, our goal in this paper was to assess whether this new policy of testing most mothers was beneficial in terms of pregnancy outcomes.
Material and methods
The data for our cohort study were collected from the Medical Birth Register of the National Institute for Health and Welfare and Hospital Discharge Register. Data in the National Institute for Health and Welfare registers were retrieved from all delivery units in Finland. The Medical Birth Register is completed for cases after data linkages to other sources (Central Population Register and Statistics Finland), and the validity of most variables has been shown to be good or very good (20, 21) . Only variables with high validity were used in this study. We studied the data from all three Helsinki metropolitan area hospitals, where the screening, diagnostic strategy, and treatment of GDM have been aligned according to the same clearly stated principals also before the CCG were applied. The study protocol was approved by the National Institute for Health and Welfare, the management of the Hospital District of Helsinki and Uusimaa, and the Ethics Committee of Women, Children and Psychiatry of the Helsinki University Hospital (reference number 22/13/03/03/2014).
We included all singleton births to women ≥18 years of age in the area from January 2006 until June 2008 and
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from July 2010 until December 2012. The flow chart of the study is illustrated in Figure 1 . The study population included 34 794 and 36 488 births, respectively. The study periods were chosen to best illustrate the pregnancy outcomes before and after the release of the CCG for GDM. In addition to analyzing both study groups, the data were divided into three subgroups according to their OGTT status. The subgroups were women diagnosed with GDM, low-risk women who had not undergone OGTT testing, and high-risk women who had negative OGTT results. A total of 334 women (1.0%) in the 2006-2008 cohort and 157 women (0.4%) in the 2010-2012 cohort were excluded from the subgroup analysis due to prepregnancy diabetes type I or II, or due to discrepancies in their reported OGTT status in the birth register data, such as a reported positive OGTT result without OGTT being performed.
The maternal and pregnancy variables included age, parity, BMI, smoking, the number of previous cesarean deliveries, the number of antenatal visits, the mode of delivery, induction, oxytocin administration, episiotomy, perineal rupture, shoulder dystocia, and postpartum blood transfusion. Children's variables included gestational age, birthweight, umbilical artery pH, Apgar scores, admission to a neonatal unit or neonatal intensive care unit (NICU), asphyxia, hypoglycemia, perinatal mortality, and the need for a respirator, resuscitation, and phototherapy. Some of these variables (for example induction, shoulder dystocia) were only reported as yes/no in the Medical Birth Register, whereas others included exact numerical data (for example pH and birthweight). Asphyxia (yes/no) was diagnosed based on clinical evidence such as preterminal cardiotocography and/or fetal scalp or umbilical cord (arterial or venous) blood pH <7.05. Perinatal mortality was the number of stillbirths (gestational age of ≥22 weeks, or birthweight from ≥500 g) and early neonatal deaths (0-6 days among live births). Hypoglycemia diagnoses (International Classification of Diseases, 10th revision P70.0 and P70.4, threshold plasma glucose value <2.6 mmol/L) were collected manually from the Hospital Discharge Register data. GDM was diagnosed by a positive 2-h 75-g OGTT with at least one abnormal plasma glucose value determined as ≥5.3 mmol/L (fasting), ≥10.0 mmol/L (1 h), and ≥8.6 mmol/L (2 h) at 24-28 weeks of gestation. High-risk cases were tested also at 12-16 weeks of gestation. In case GDM was diagnosed, mothers received dietary and lifestyle counseling in the primary healthcare centers followed by self-monitoring of glucose concentrations. If the fasting glucose levels were ≥5.5 mmol/L or postprandial values were ≥7.8 mmol/L twice within 1 week, the mother was referred to the hospital's maternity clinic, where the need for insulin treatment was assessed. In some rare cases metformin was chosen, for example mother had pregestational BMI > 35 kg/m 2 or polycystic ovarian syndrome.
The data were analyzed using EXCEL FOR WINDOWS and SPSS FOR WINDOWS version 20.0 (IBM Corp., Armonk, NY, USA). Continuous variables were compared using a two-tailed Student's t-test. Pearson's chi-square test and tests for relative proportions were used for categorical variables. Values of p <0.05 were considered statistically significant.
Results
In this study, the prevalence of GDM was 7. In the first cohort, 32.8% of the overweight (BMI ≥ 25 kg/m 2 ) nulliparous women had not undergone OGTT, whereas this percentage in the later cohort was only 8.4% (p < 0.001), demonstrating the application of CCG. The women who did not require testing for GDM in 2010-2012 were significantly younger, more often multiparous, and had fewer antenatal visits compared with women in the 2006-2008 cohort. Furthermore, the women whose screening results were negative for GDM were more often nulliparous, thinner, and had fewer antenatal visits in 2010-2012 than the same subgroup in 2006-2008.
The general trends in all deliveries from 2006-2008 to 2010-2012 were increases in the gestational age (from 39.2 to 39.8 weeks; p < 0.001), the number of instrumental deliveries (9.0% vs. 10.3%; p < 0.001), inductions (16.9% vs. 21.5%; p < 0.001), and the use of oxytocin (12.4% vs. 33.4%; p < 0.001). Fewer episiotomies were carried out (25.6% vs. 22.2%; p < 0.001). There was no change in the overall cesarean section rate (18.0% vs. 17.8%; p = 0.51). The analysis of neonatal outcomes demonstrated no change in birthweight (3510 g vs. 3495 g; p = 0.64), Apgar scores <7 at 5 min (4.7% in both cohorts; p = 0.93), or the perinatal mortality rate (5.2 vs. 4.2&; p = 0.06). However, there were significantly lower rates of newborns with birthweight > 4500 g (2.7% vs. 2.4%; p = 0.007), resuscitation (2.2% vs. 1.7%; p < 0.001), and asphyxia (10.6% vs. 6.6%; p < 0.001). The incidence of hypoglycemia increased from 0.9 to 2.15%; p < 0.001. More detailed information about pregnancy and perinatal outcomes in all deliveries is in the Supplementary material (Table S2) .
Pregnancy and neonatal outcomes in the three subgroups are presented in Tables 1-3 . Since the CCG were introduced, the rate of instrumental deliveries, the numbers of cesarean sections and shoulder dystocias, Apgar scores <7 at 5 min, pH, and perinatal mortality did not change in GDM pregnancies. The use of oxytocin and the number of inductions increased in all subgroups as well as when the whole study populations 2 ) children increased, whereas in the same obesity class group of women with GDM, it decreased.
The results of the population with GDM were also adjusted according to the gestational age, with a prematurity incidence of 5.7% in 2008-2010 and 6.0% in 2010-2012 (p = 0.67). After the adjustment, the results remained unchanged.
Discussion
The CCG were created to improve the pregnancy outcomes and to ensure the well-being of the fetuses and newborns (18) . We observed that despite the fact that the OGTT number multiplied, it had little effect on pregnancy and children's outcomes. When the CCG was applied and the screening shifted from risk-based to comprehensive, more GDM was diagnosed in younger women with a normal BMI who had babies with normal birthweights (Table 1 and see Supplementary material,  Table S1 ). GDM had a minimal effect on their pregnancy outcomes, their delivery modes and their children's postnatal glucose testing. The modes of delivery in women with GDM remained the same as before the CCG's release, whereas in the subgroups with negative OGTT and low-risk mothers without OGTT, the operative deliveries became less frequent. One could argue that GDM treatment might still be insufficient or GDM diagnosis might lead to unnecessary iatrogenic interventions including inductions or changes in the delivery mode. Official guidelines in obstetrical care were not implemented during our study period.
The global incidence of GDM was estimated to be 5% in 2008 according to a Lancet editorial (12) . In the HAPO study, the prevalence of GDM in the research population in the USA was 16.1% (13) . In our study population, the prevalence of GDM reached 11.3% in the period of 2010-2012, and it has continued to rise (14) . The increasing prevalence of GDM is closely related to the obesity epidemic, which also affects the reproductive population (1). The proportion requiring insulin treatment remained unchanged in our GDM study population. In a previous population-based Finnish study, the proportion of insulin-treated women with GDM was reduced from 21.8% in 2006 to 13.3% in 2010 (17) , hence approaching the prevalence in our study population. According to our results, the comprehensive screening method was unable to detect more women with a severe form of GDM who require insulin treatment.
The OGTT number doubled in the Helsinki metropolitan area, which illustrates that the CCG were accepted and followed. The number of overweight, nulliparous women who missed the testing was significantly reduced from 32.8% to 8.4%. The CCG aimed to test nearly all the mothers, but clearly that still remains a challenge. The challenge persisted also at the national level, when only 56.8% of the mothers underwent OGTT in 2012-2013 (22) . We can only speculate the reason behind this. Women might refuse the testing due to fear of nausea or vomiting, or due to a feeling of invulnerability to the condition. Healthcare personnel might also need to improve referral practice and encourage women to participate. Children's birthweight decreased in our study population including the GDM group; this trend was also seen in the Finnish Birth Register data in past decades. In all deliveries in Finland, the mean birthweight was 3552 g in 1990; in 2006, it was 3499 g and 3498 g in 2012 (22) . Some have argued that it is due to the well-organized treatment of GDM in Finland (22) . According to our results this cannot be the only factor, as the birthweight decreased in all groups, even with mothers without GDM. Both women with GDM and women with negative OGTT had fewer newborns with birthweight >4500 g in 2010-2012 than in the earlier cohort, which may be due to the increased number of inductions in these groups.
When we analyzed the birthweights in relation to the mothers' BMI, we observed that there was one group of mothers whose children's birthweight was on the rise: severely and morbidly obese mothers without GDM (Figure 2 ). In contrast, the birthweight of the children of obese women with GDM has decreased since the release of the CCG, suggesting that their care has improved. Our results show that we need to target more specifically all severely or morbidly obese women, regardless of their OGTT status. It has been shown that (23) . Several other lifestyle intervention trials have been undertaken, resulting in reduced gestational weight gain (24) (25) (26) or positive metabolic changes (24) , but the incidence of GDM has not been reduced (24) (25) (26) (27) . Dietary advice and lifestyle interventions are relatively inexpensive, noninvasive options of care, which could be personalized according to women's individual requirements. However, it can be argued whether this approach would lead to significant changes in pregnancy outcomes for this obstetrical highrisk group.
Children's other outcomes in the GDM group remained largely unchanged over the two periods (Tables 1-3 ). The positive changes in the GDM group were smaller birthweight, fewer NICU admissions, and less frequently diagnosed asphyxia. However, the same results were seen in mothers with negative OGTT results. The incidence of neonatal complications in general was very low, resulting in limitations in the statistical power of the findings. This may have affected the results, even with our relatively large study population. All children of mothers with GDM are under close observation for signs of hypoglycemia, and their blood glucose levels are routinely monitored during the first 1 or 2 days, depending on the severity of GDM. The children of non-GDM mothers are not routinely screened, but are only followed for symptoms of hypoglycemia. The incidence of perinatal hypoglycemia doubled in both the GDM and unscreened groups, whereas it was lower in children whose mothers had normal OGTT results. There were no changes in the official guidelines about screening of hypoglycemia in newborns during our study period. One could argue that as the number of newborns of mothers with GDM is increased, the screening of hypoglycemia is more customary and it is more commonly searched for even in newborns of undiagnosed mothers.
The main limitation of our study is that it was solely register-based and regional. The results could have been affected by missing information in the hospital data and mistyping and misinterpreting the hospital data during data transfer from the hospitals to the national Birth Register. Some women with diabetes type I or II could have been mistakenly included in the subgroups for data analysis as a result of difficulties in identifying them definitely from the Birth Register data. However, the large population in our study was concentrated on three hospitals with specific guidelines for reporting Birth Register data, which should reduce the impact and importance of these errors. Our study population in the Helsinki metropolitan area hosts the oldest, most nulliparous mothers with the smallest BMI in Finland (22), who do not have an excessively high risk of GDM. Despite these demographic facts, the CCG are the same nationally, and our results could be generalized while keeping this limitation in mind.
In conclusion, this study has demonstrated that the implementation of national guidelines for GDM and the change from risk-based to comprehensive screening has not improved the pregnancy outcomes of women with GDM. Rather, the most important changes following the CCG have been the doubling of the number of women being tested and the increased prevalence of the disease. The resultant increased maternal stress and anxiety, increased use of healthcare resources, increased hypoglycemia testing of the newborn, and the increased costs should not be overlooked. Therefore testing women on this scale cannot be fully supported; rather, resources should be more focused on severely and morbidly obese women, regardless of their OGTT status. Future research should focus on finding the medically relevant and evidence-based GDM diagnostic strategy and treatment protocol.
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